Formulation Options In Nasal Drug Delivery

Upperton had an article published in Edition 119 ONdrugDeliver in May 2021

In the article Richard Johnson, CEO and founder of Upperton,  discusses the advantages of nasal delivery and why there is growing interest in this route of administration, as well as considering some of the challenges that may arise during the development of nasal formulations for use in the clinic, and the regulatory and testing requirements associated with them.

Find the full e-magazine here  or to go straight to the article here